Compare Aurora Cannabis Inc (ACB) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

SPMO trades at $152.98, up 1.43% with neutral technical signals despite bullish moving averages. The ETF shows strong momentum performance with 7.5% June gains and 44.4% Q2 returns, heavily weighted toward technology stocks (55%) including AI beneficiaries. Recent institutional activity shows mixed positioning with several advisors increasing stakes while others reduced exposure.

Outlook remains constructive given AI-driven momentum strength, though elevated valuations and potential rotation risks warrant monitoring. The ETF's rules-based methodology targeting top S&P 500 momentum performers positions it for continued growth, but concentration in technology exposes it to sector-specific volatility.